Optimal timing of pegfilgrastim in DCF regimen for advanced esophageal cancer
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000023393
- Lead Sponsor
- Kyoto Prefectural University of Medicine, Gatroenterology and Hepatology
- Brief Summary
The incidence of grade 4 neutropenia was 8.7 percent. No patient experienced FN. Of the 19 patients who received two cycles of DCF, one required a dose reduction/treatment delay due to hematological toxicity in the second treatment cycle. No serious adverse events, considered relevant to pegfilgrastim, were observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Not provided
1)Synchronous or metachronous malignancies other than carcinoma in situ or mucosal carcinoma 2)Evidence of any other serious disease 3)Active local or systemic infection under treatment 4)History of serious allergic reaction 5)Pulmonary fibrosis or interstitial pneumonitis detected by chest X-ray 6)primary hematologic disease 7)Serious allergic reaction to Docetaxel, cisplatin, 5FU and pegfilgrastim 8)Massive pericardial effusion, pleural effusion or ascites 9)Received radiotherapy within 4 weeks before 10)Received drugs of other clinical tests within 4 weeks before 11)History of receiving pegfilgrastim before 12)Pregnant or lactating female 13)Judged inappropriate by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of less than 500/uL of neutrophillic number confirmed after 1st course.
- Secondary Outcome Measures
Name Time Method